Clinical Trial Update: FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CXA-10 in primary focal segmental glomerulosclerosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• CXA-10

Snippet

Sponsor: Complexa, Inc. | Conditions: Primary Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED